Home > Dermatology > SPIN 2022 > Best of the Posters > Comorbid anxiety and depression may benefit from psoriasis treatment with certolizumab

Comorbid anxiety and depression may benefit from psoriasis treatment with certolizumab

Presented By
Prof. April Armstrong, Keck School of Medicine of USC, CA, USA
Conference
SPIN 2022
Trial
Phase 3, CIMPASI-1, CIMPASI-2
Doi
https://doi.org/10.55788/9355ac07
Treatment of psoriasis with certolizumab could also have a positive impact on depression or anxiety. This is suggested by the results of a pooled analysis of the phase 3 CIMPASI-1 and -2 trials, in which almost half of the depressive and nearly one-third of the anxiety patients achieved a substantial reduction in their disease scores. A diagnosis of depression and anxiety is more likely in patients with psoriasis than in the general population, and an association between the depression risk and the disease severity has also been identified [1,2]. But does the treatment of psoriasis with certolizumab pegol also affect comorbid anxiety or depression? Pooled data from 3-year phase 3 CIMPASI-1 and -2 trials (NCT02326298 and NCT02326272) was used to assess the r...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on